Tiumbio Co., Ltd.

7 patents currently held · Updated Nov 15, 2026

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Ending by 2030

Jun 2031

Next term end

When these terms end

5 yrs10 yrs20 yrs

Held patents by the year their term ends

20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

No maintenance fee falls due on this company's record before Nov 15, 2027.

Recent changes

1 of the patents on this record was granted since Aug 17, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.

Showing 1 to 7 of 7

Patent	Title	Status	Expires	Confidence
US 10,696,960	Fusion protein having factor VII activity In force Ends no later than Jun 7, 2031 · From the USPTO record	In force	Ends no later than Jun 7, 2031	From the USPTO record
US 10,155,763	2-pyridyl substituted imidazoles as ALK5 and/or ALK4 inhibitors In force Term ends Sep 21, 2032 · From the USPTO record	In force	Term ends Sep 21, 2032	From the USPTO record
US 9,617,328	Fusion protein having factor IX activity In force Term ends Jan 4, 2033 · From the USPTO record	In force	Term ends Jan 4, 2033	From the USPTO record
US 9,481,684	Gonadotropin releasing hormone receptor antagonists, method for the preparation thereof and pharmaceutical composition comprising the same In force Term ends Feb 28, 2033 · From the USPTO record	In force	Term ends Feb 28, 2033	From the USPTO record
US 9,987,339	Pharmaceutical composition with improved stability containing factor VII fusion protein In force Term ends Dec 16, 2034 · From the USPTO record	In force	Term ends Dec 16, 2034	From the USPTO record
US 12,227,513	Salt and crystalline form of furopyrimidine compound and pharmaceutical use thereof In force Term ends Mar 24, 2042 · From the USPTO record	In force	Term ends Mar 24, 2042	From the USPTO record
US 12,788,752	Pharmaceutical Composition for Preventing or Treating Tumor, and Use Thereof In force Term ends Jul 9, 2043 · High confidence	In force	Term ends Jul 9, 2043	High confidence

Also on record, not counted in the 7: 3 lapsed for an unpaid fee · 1 ended at full term. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Export every term end as CSV · Pro

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

1 abandoned

List them